Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G ...

Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the ...

The VALIANT Phase 3 trial shows that pegcetacoplan significantly reduces proteinuria and stabilises kidney function in ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® ...

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

Vicky Ograin, MBA, RVT, VTS (Nutrition), discussed the gastrointestinal microbiome and how it can be modulated with ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

Even if there are problems with the function, the kidneys do not have any special symptoms, making it difficult to recognize ...

The causes of kidney damage are varied, but more or less include Chronic Kidney Disease (CKD), Acute Kidney Injury, Diabetes, ...

Travere Therapeutics, Inc., today announced that the Company will present seven abstracts at the upcoming European Renal Association (ERA) Congress in Vienna, Austria, June 4-7. Presentations will ...